000009737 001__ 9737
000009737 005__ 20231129124951.0
000009737 0247_ $$2DOI$$a10.6083/pz50gw80v
000009737 037__ $$aETD
000009737 245__ $$aEvaluation and implementation of a dosimetry protocol for Lutetium Lu 177 DOTATATE for the treatment of gastroenteropancreatic-neuroendocrine tumors
000009737 260__ $$bOregon Health and Science University
000009737 269__ $$a2022
000009737 336__ $$aThesis
000009737 502__ $$bM.S.
000009737 520__ $$aLutathera is a radiopharmaceutical used to treat gastroenteropancreatic-neuroendocrine tumors(GEP-NETs) in adults that are positive for hormone receptor somatostatin. The cur-rent FDA-approved label describes Lutathera treatment as four 200 mCi cycles given every eight weeks. If the patient reacted negatively to toxicity caused by acute myelosuppression which is a decrease in bone marrow activity which leads to fewer red blood cells, white blood cells, and platelets, or nephrotoxicity(1), the dose is halved to 100 mCi. If the patient continues to experience toxicity from the radiopharmaceutical, the treatment is stopped. A dosimetry protocol will outline the imaging modality utilized to obtain quantitative infor-mation about the distribution of Lutathera, the frequency at which imaging needs to occur, and the time after injection that imaging needs to occur. Personalized dosimetry would also allow for an increase of prescribed activity with the gain in knowledge of the proximity to dose thresholds leading to deterministic effects for organs at risk.
000009737 650__ $$aRadiopharmaceuticals$$031493
000009737 650__ $$aRadiometry$$025112
000009737 650__ $$aNuclear Medicine$$023036
000009737 691__ $$aSchool of Medicine$$041369
000009737 7001_ $$aStoller, Jared
000009737 8564_ $$99866da7d-cddf-42d9-9925-53b415a78f67$$s3793603$$uhttps://digitalcollections.ohsu.edu/record/9737/files/Stoller.Jared.2022.pdf
000009737 905__ $$a/rest/prod/pz/50/gw/80/pz50gw80v
000009737 909CO $$ooai:digitalcollections.ohsu.edu:9737$$pstudent-work
000009737 980__ $$aTheses and Dissertations